154 search results for: type 2 inflammation

UCARE <b>2</b>0<b>2</b>3: Immune Cells and Mediators Essential for Driving CSU Pathology

expert video

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

1 min

Dermatology

Dr. Saini describes immune cells and mediators beyond mast cells that are also essential for helping to drive CSU pathology.

Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

5 min

Dermatology

An infographic summarizing the clinical manifestations and pathophysiological processes of PN.

expert video

ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE

13 min

Gastroenterology

Dr. Dhandapani Ashok discusses patient and caregiver burden in pediatric EoE and the challenges with identifying EoE in a young patient population.

UCARE <b>2</b>0<b>2</b>3: CSU – The Brazil Perspective

expert video

UCARE 2023: CSU – The Brazil Perspective

6 min

Dermatology

Dr. Ensina guides discussions on the perspective of CSU management in Brazil.

expert video

Managing the Risk of Fibrostenosis in EoE

2 min

Gastroenterology

Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

UCARE <b>2</b>0<b>2</b>3: Non-Histaminergic Neuronal Sensitization in CSU

expert video

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

1 min

Dermatology

Dr. Kim highlights the role of non-histaminergic neuronal sensitization in CSU via cytokines.

UCARE <b>2</b>0<b>2</b>3: Emerging Clinical Trial Data in CSU

expert video

UCARE 2023: Emerging Clinical Trial Data in CSU

13 min

Dermatology

Dr. Maurer explores current clinical data from leading emerging therapies in CSU.

UCARE <b>2</b>0<b>2</b>3: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab

expert video

UCARE 2023: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab

1 min

Dermatology

Dr. Maurer summarises the implications of different modes of action of dupilumab, remibrutinib and barzolvolimab.

expert video

Skin Dysbiosis in AD

17 min

Dermatology

Dr. Lisa Beck discusses how S. aureus colonization contributes to a disrupted skin microbiome, skin barrier dysfunction, disease flares and increased disease severity in AD, and how blocking IL-4 and IL-13 can reduce S. aureus colonization.

ERS <b>2</b>0<b>2</b>4 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

expert video

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

45 min

Pulmonology

Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GermanyChange country/region